JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

Amazing Peptide linked at the end: https://www.youtube.com/watch?v=T9KJ8HGRmwM

0:00 - Introduction
0:37 - Massive Lean Mass Loss
1:27 - Muscle Loss
4:00 - Look at the Function, my Boy!

References
[Study 777] Langer HT, Gilmore NK, Hayden CMT, et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Rep Med. 2026;7(3):102665. doi:10.1016/j.xcrm.2026.102665

Funding/Conflicts: Public Funding: From the study, support included NIH grant S10-OD025098, UC Davis T32 in Pharmacology grant T32 GM144303, National Institute of Diabetes and Digestive and Kidney Diseases grants DK139663 and DK139565, the Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen, the Bundesministerium für Forschung, Technologie und Raumfahrt, German Research Foundation grants, the German Center for Diabetes Research, and the European Union; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no direct industry funding source was reported, but several conflicts were declared, including prior employment or current employment with Boehringer Ingelheim and Eli Lilly, consulting for Actimed Therapeutics, Almac Discovery, Alchemab Therapeutics, Novartis, and several food or biotech companies, co-founder roles in SinewUS and Bluewater Biotech, stock holdings in Eli Lilly and Novo Nordisk, and speaking fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Merck, AstraZeneca, Rhythm Pharmaceuticals, and Mercodia.

[Study 778] Linge J, Birkenfeld AL, Neeland IJ. Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?. Circulation. 2024;150(16):1288-1298. doi:10.1161/CIRCULATIONAHA.124.067676

Funding/Conflicts: Public Funding: From the study, no public funding source was reported, as the listed source of funding was “None”; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no industry funding source was reported, but conflicts included author relationships with AMRA Medical, Eli Lilly, BioMarin, Boehringer-Ingelheim/Lilly Alliance, Bayer, Novo Nordisk, AstraZeneca, Daiichi Sankyo, and related advisory, consulting, speaker, travel, employment, shareholder, and research-support roles.

[Study 779] Karasawa T, Choi RH, Meza CA, Rout S, Drummond MJ, Chaix A, Funai K. Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice. Cell Metab. 2025;37(8):1619-1620. doi:10.1016/j.cmet.2025.07.004.

Funding/Conflicts: Public Funding: From the study, the work was supported by NIH grants DK107397, DK127979, GM144613, AG074535, CA286584, AG065993, AG076075, and AG086328, and by a Japan Society for the Promotion of Science Fellows grant-in-aid, 24KJ2039; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, no industry funding source was reported, and the authors declared no competing interests.

[Study 780] Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. doi:10.1111/dom.16275

Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the work was funded by Eli Lilly and Company; conflicts included speaker, lecture, advisory, or consulting relationships with Eli Lilly and Company and other companies, and several authors were employees and shareholders of Eli Lilly and Company.

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.